Begin main content

Avastin for Cervical Cancer - Details

Project Number pCODR 10045
Brand Name Avastin
Generic Name Bevacizumab
Strength 25mg/mL
Tumour Type Gynecology
Indication Cervical Cancer
Funding Request In combination with chemotherapy for the treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix
Review Status Notification to Implement Issued
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Hoffmann-La Roche Limited
Submitter Hoffmann-La Roche Limited
Submission Date October 27, 2014
Submission Deemed Complete November 3, 2014
Submission Type New Indication
Prioritization Requested Requested and Not Granted
Stakeholder Input Deadline ‡ November 10, 2014
Check-point meeting December 16, 2014
pERC Meeting February 19, 2015
Initial Recommendation Issued March 5, 2015
Feedback Deadline ‡ March 19, 2015
Final Recommendation Issued March 23, 2015
Notification to Implement Issued April 8, 2015

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.